{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:46:45Z","timestamp":1754110005127,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T00:00:00Z","timestamp":1449532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10147-015-0926-0","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T06:14:28Z","timestamp":1449641668000},"page":"531-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuru","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunekazu","family":"Hishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,8]]},"reference":[{"key":"926_CR1","unstructured":"Rare Cancers Europe. In: http:\/\/www.rarecancerseurope.org\/ . Accessed Aug 2015"},{"key":"926_CR2","doi-asserted-by":"crossref","first-page":"S1689","DOI":"10.1097\/JTO.0b013e31821e7afe","volume":"6","author":"F Detterbeck","year":"2011","unstructured":"Detterbeck F, Huang J (2011) ITMIG definitions and policies. J Thorac Oncol 6:S1689\u2013S1755","journal-title":"J Thorac Oncol"},{"key":"926_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","volume":"12","author":"N Girard","year":"2012","unstructured":"Girard N (2012) Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 12:685\u2013695","journal-title":"Expert Rev Anticancer Ther"},{"key":"926_CR4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","volume":"11","author":"DS Ettinger","year":"2013","unstructured":"Ettinger DS, Riely GJ, Akerley W et al (2013) Thymomas and thymic carcinomas: clinical practice guidelines in oncology. J Natl Compr Canc Netw 11:562\u2013576","journal-title":"J Natl Compr Canc Netw"},{"key":"926_CR5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"926_CR6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00404-010-1757-x","volume":"283","author":"A Bruning","year":"2011","unstructured":"Bruning A, Mylonas I (2011) New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. Arch Gynecol Obstet 283:1087\u20131096","journal-title":"Arch Gynecol Obstet"},{"key":"926_CR7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","volume":"12","author":"LP Jordheim","year":"2011","unstructured":"Jordheim LP, Seve P, Tredan O et al (2011) The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12:693\u2013702","journal-title":"Lancet Oncol"},{"key":"926_CR8","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","volume":"10","author":"G Palmieri","year":"2014","unstructured":"Palmieri G, Buonerba C, Ottaviano M et al (2014) Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. Future Oncol 10:2141\u20132147","journal-title":"Future Oncol"},{"key":"926_CR9","unstructured":"Travis W, Brambilla W, M\u00fcller-Hermelink H et al (2004) Pathology and genetics of tumors of the lung, pleura, thymus and heart. In: Chapter 3 Tumours of the thymus. Third edition. World Health Organization classification of tumors, IARC press, Lyon. Volume 10:145-248"},{"key":"926_CR10","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","volume":"5","author":"A Masaoka","year":"2010","unstructured":"Masaoka A (2010) Staging system of thymoma. J Thorac Oncol 5:S304\u2013S312","journal-title":"J Thorac Oncol"},{"key":"926_CR11","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/JTO.0b013e3181f13682","volume":"5","author":"J Huang","year":"2010","unstructured":"Huang J, Detterbeck FC, Wang Z et al (2010) Standard outcome measures for thymic malignancies. J Thorac Oncol 5:2017\u20132023","journal-title":"J Thorac Oncol"},{"key":"926_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"926_CR13","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/JTO.0000000000000296","volume":"9","author":"MF Benveniste","year":"2014","unstructured":"Benveniste MF, Korst RJ, Rajan A et al (2014) A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol 9:S119\u2013S124","journal-title":"J Thorac Oncol"},{"key":"926_CR14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","volume":"12","author":"PJ Loehrer Sr","year":"1994","unstructured":"Loehrer PJ Sr, Kim K, Aisner SC et al (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12:1164\u20131168","journal-title":"J Clin Oncol"},{"key":"926_CR15","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","volume":"6","author":"T Agatsuma","year":"2011","unstructured":"Agatsuma T, Koizumi T, Kanda S et al (2011) Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 6:2130\u20132134","journal-title":"J Thorac Oncol"},{"key":"926_CR16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","volume":"26","author":"F Hirai","year":"2015","unstructured":"Hirai F, Yamanaka T, Taguchi K et al (2015) A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 26:363\u2013368","journal-title":"Ann Oncol"},{"key":"926_CR17","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060\u20132065","journal-title":"J Clin Oncol"},{"key":"926_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","volume":"141","author":"Y Okuma","year":"2015","unstructured":"Okuma Y, Saito M, Hosomi Y et al (2015) Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 141:323\u2013331","journal-title":"J Cancer Res Clin Oncol"},{"key":"926_CR19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","volume":"14","author":"G Giaccone","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14:814\u2013820","journal-title":"J Clin Oncol"},{"key":"926_CR20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyf059","volume":"32","author":"S Umemura","year":"2002","unstructured":"Umemura S, Segawa Y, Fujiwara K et al (2002) A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol 32:262\u2013265","journal-title":"Jpn J Clin Oncol"},{"key":"926_CR21","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","volume":"17","author":"MS Highley","year":"1999","unstructured":"Highley MS, Underhill CR, Parnis FX et al (1999) Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17:2737\u20132744","journal-title":"J Clin Oncol"},{"key":"926_CR22","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1200\/jco.2006.24.18_suppl.7079","volume":"24","author":"P Loehrer","year":"2006","unstructured":"Loehrer P, Yiannoutsos C, Dropcho S (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Am Soc Clin Oncol 24:7079 (abstract)","journal-title":"Am Soc Clin Oncol"},{"key":"926_CR23","first-page":"1331","volume":"17","author":"CH Hsu","year":"1997","unstructured":"Hsu CH, Yeh KH, Cheng AL (1997) Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res 17:1331\u20131334","journal-title":"Anticancer Res"},{"key":"926_CR24","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"K Oberg","year":"2004","unstructured":"Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966\u2013973","journal-title":"Ann Oncol"},{"key":"926_CR25","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","volume":"6","author":"N Girard","year":"2011","unstructured":"Girard N, Lal R, Wakelee H et al (2011) Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol 6:S1749\u2013S1755","journal-title":"J Thorac Oncol"},{"key":"926_CR26","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","volume":"29","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Petrini I, Rajan A et al (2011) Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 29:4820\u20134827","journal-title":"J Clin Oncol"},{"key":"926_CR27","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Strobel","year":"2004","unstructured":"Strobel P, Hartmann M, Jakob A et al (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625\u20132626","journal-title":"N Engl J Med"},{"key":"926_CR28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","volume":"103","author":"P Strobel","year":"2010","unstructured":"Strobel P, Bargou R, Wolff A et al (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196\u2013200","journal-title":"Br J Cancer"},{"key":"926_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thorsurg.2010.08.011","volume":"21","author":"N Girard","year":"2011","unstructured":"Girard N, Mornex F (2011) The role of radiotherapy in the management of thymic tumors. Thorac Surg Clin 21:99\u2013105","journal-title":"Thorac Surg Clin"},{"key":"926_CR30","first-page":"7527","volume":"32","author":"PA Zucali","year":"2014","unstructured":"Zucali PA, De Pas TM, Palmieri G et al (2014) Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. ASCO Meeting Abstracts 32:7527","journal-title":"ASCO Meeting Abstracts"},{"key":"926_CR31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas A, Rajan A, Berman A et al (2015) Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16:177\u2013186","journal-title":"Lancet Oncol"},{"key":"926_CR32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","volume":"15","author":"A Rajan","year":"2014","unstructured":"Rajan A, Carter CA, Berman A et al (2014) Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 15:191\u2013200","journal-title":"Lancet Oncol"},{"issue":"13","key":"926_CR33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Tourneau Le","year":"2015","unstructured":"Le Tourneau C, Delord JP, Goncalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16(13):1324\u20131334","journal-title":"Lancet Oncol"},{"key":"926_CR34","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S1470-2045(08)70280-8","volume":"9","author":"D Lev\u00eaque","year":"2008","unstructured":"Lev\u00eaque D (2008) Off-label use of anticancer drugs. Lancet Oncol 9:1102\u20131107","journal-title":"Lancet Oncol"},{"key":"926_CR35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","volume":"88","author":"Y Katsuya","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H et al (2015) Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 88:154\u2013159","journal-title":"Lung Cancer"},{"key":"926_CR36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ et al (2015) Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol 10:500\u2013508","journal-title":"J Thorac Oncol"},{"key":"926_CR37","doi-asserted-by":"crossref","unstructured":"Okuma Y, Hosomi Y, Miyamoto S, et al (2015) Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. J Clin Oncol 33:suppl; abstr e18565","DOI":"10.1200\/jco.2015.33.15_suppl.e18565"},{"key":"926_CR38","first-page":"299","volume":"31","author":"T Koizumi","year":"2011","unstructured":"Koizumi T, Agatsuma T, Komatsu Y et al (2011) Successful S-1 monotherapy for chemorefractory thymic carcinoma. Anticancer Res 31:299\u2013301","journal-title":"Anticancer Res"},{"key":"926_CR39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cllc.2014.10.006","volume":"16","author":"Y Okuma","year":"2015","unstructured":"Okuma Y, Hosomi Y, Takahashi S et al (2015) Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. Clin Lung Cancer 16:221\u2013227","journal-title":"Clin Lung Cancer"},{"key":"926_CR40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2012.12.012","volume":"80","author":"Y Okuma","year":"2013","unstructured":"Okuma Y, Hosomi Y, Takagi Y et al (2013) Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 80:75\u201380","journal-title":"Lung Cancer"},{"key":"926_CR41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","volume":"87","author":"Y Liang","year":"2015","unstructured":"Liang Y, Padda SK, Riess JW et al (2015) Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer 87:34\u201338","journal-title":"Lung Cancer"},{"key":"926_CR42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jjco\/hyv046","volume":"45","author":"N Watanabe","year":"2015","unstructured":"Watanabe N, Umemura S, Niho S et al (2015) Docetaxel for platinum-refractory advanced thymic carcinoma. Jpn J Clin Oncol 45:665\u2013669","journal-title":"Jpn J Clin Oncol"},{"key":"926_CR43","first-page":"7580","volume":"33","author":"HA Wakelee","year":"2015","unstructured":"Wakelee HA, Padda SK, Burns M et al (2015) 2015) Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). ASCO Meet Abstr 33:7580","journal-title":"ASCO Meet Abstr"},{"key":"926_CR44","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","volume":"29","author":"G Giaccone","year":"2011","unstructured":"Giaccone G, Rajan A, Berman A et al (2011) Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 29:2052\u20132059","journal-title":"J Clin Oncol"},{"key":"926_CR45","first-page":"7526","volume":"32","author":"B Besse","year":"2014","unstructured":"Besse B, Garassino MC, Rajan A et al (2014) A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). ASCO Meet Abstr 32:7526","journal-title":"ASCO Meet Abstr"},{"key":"926_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","volume":"89","author":"MA Gubens","year":"2015","unstructured":"Gubens MA, Burns M, Perkins SM et al (2015) A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. Lung Cancer 89:57\u201360","journal-title":"Lung Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-015-0926-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0926-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T10:20:47Z","timestamp":1599906047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-015-0926-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0926-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2015,12,8]]}}}